Original ArticleEverolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH
Keywords: فسفاتیدیلینواستیل 3-کیناز; Acidosis; Tumor microenvironment; BRAFV600E melanoma cells; Vemurafenib; Trametinib; Everolimus; MAPK; mitogen-activated protein kinase; RTK; receptor tyrosine kinases; ERK; extracellular signal-regulated kinases; PI3K; phosphatidylinositol 3-kinase; AKT;